Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Wednesday, June 4, 2025 1 min read
Key Takeaway: RAD has successfully dosed the first patient in its therapeutic trial of 177Lu-RAD202. This marks a significant milestone in the development of this treatment, indicating progress in clinical research. The trial aims to evaluate the efficacy and safety of the drug, potentially offering new therapeutic options for patients.
Price reaction · baseline $5.02 (2025-06-04T18:47:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
+2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in the therapeutic trial of 177Lu-RAD202.
  • Significant progress in clinical development.
  • Potential for innovative treatment options.

Full Press Release Details

• Announcements
• Price Sensitive
• June 4, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• February 25, 2025
• Announcements
• June 20, 2024
• Announcements
• January 24, 2022
• RAD Articles
• September 30, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the 177Lu-RAD202 trial about?

The trial aims to evaluate the efficacy and safety of 177Lu-RAD202 as a therapeutic option.

Who was the first patient dosed in the trial?

The article does not specify the identity of the first patient dosed.

What phase is the 177Lu-RAD202 trial in?

The trial is classified as a Phase 1/2a clinical study.

What company is conducting the trial?

The trial is being conducted by RAD.

Tags: RADX Viatris Investor Conferences Healthcare RAD 177Lu-RAD202 clinical trial therapeutic study FDA
Last updated: Jun 4, 2025